Search results
Showing 1756 to 1770 of 9008 results
Zasocitinib for treating moderate to severe plaque psoriasis [ID6700]
Awaiting development Reference number: GID-TA11926 Expected publication date: TBC
In development Reference number: GID-TA11718 Expected publication date: TBC
AI technologies to aid the scoring and interpretation of diagnostic sleep studies
Awaiting development Reference number: GID-HTG10174 Expected publication date: TBC
Awaiting development Reference number: GID-HTG10177 Expected publication date: TBC
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]
In development Reference number: GID-TA10249 Expected publication date: TBC
Ibrutinib for treating relapsed or refractory follicular lymphoma [ID1251]
In development Reference number: GID-TA10223 Expected publication date: TBC
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]
In development Reference number: GID-TA11334 Expected publication date: TBC
Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]
In development Reference number: GID-TA11859 Expected publication date: TBC
In development Reference number: GID-HTE10072 Expected publication date: 19 November 2026
Sepiapterin for treating hyperphenylalaninaemia in phenylketonuria in people of any age [ID6750]
Awaiting development Reference number: GID-TA11982 Expected publication date: TBC
Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579]
In development Reference number: GID-TA11780 Expected publication date: TBC
Elranatamab for treating relapsed or refractory multiple myeloma after 2 treatments [ID6464]
Awaiting development Reference number: GID-TA11661 Expected publication date: TBC
Awaiting development Reference number: GID-TA11673 Expected publication date: TBC
Awaiting development Reference number: GID-TA11308 Expected publication date: TBC
Awaiting development Reference number: GID-TA11437 Expected publication date: TBC